The 2021 US Patient Study of Asthma Medications
11 Jul 2022
Small molecular drug
DUBLIN, July 11, 2022 /PRNewswire/ -- The "The 2021 US Patient Study of Asthma Medications" report has been added to
ResearchAndMarkets.com's offering.
OTC meds are taking on a bigger role in asthma treatment and sufferers are reporting higher satisfaction levels with these OTCs than in the past. The 2021 Adult Patient Study of Asthma Medications is part of a continuing series of surveys designed to provide subscribers with invaluable insights into adult asthma sufferers' awareness, usage and attitudes toward prescription and non-prescription asthma medication.
Phase I - General Population Survey
Incidence of diagnosed asthma among adults
Report of asthma among other household members
Take medications for asthma
Phase II - Survey Among Adult Asthmatics Taking Medication
Asthma history, symptoms and triggers
Severity of asthma
Managing/treating asthma, including use of Rx and non-Rx medications, diet and role of physician
Brand awareness and usage, including brand switching and loyalty
Changing attitudes towards asthma
A market segmentation analysis was conducted to provide insights on how asthma medicators segment along attitudinal dimensions.
Electronic Deliverables
Summary Volume - Written analysis in PowerPoint including Key Findings, Summary and Market Segmentation.
Top-line Trends Volume - Trended top-line tables detailing findings from all questions.
Excel Tabulations - All survey questions cross-tabulated by key demographics (see below for list of variables)
Key Topics Covered:
INTRODUCTION
METHODOLOGY
KEY FINDINGS
S
UMMARY OF FINDINGS
Phase I: General Population Survey
Incidence of Asthma & Treatment
Diagnosed Asthma by Demographics
Household Members With Asthma
Phase II: Survey of Adult Medicators
Section 1: Living With Asthma
Severity of Asthma
Severity of Asthma By Subgroups
Persistence & Seasonality of Asthma
Age When Asthma Was Diagnosed
Asthma Interferes With Daily Activities
Frequency of Asthma Symptoms
Asthma SymptomsAsthma Symptoms Considered Most Bothersome
Asthma Related Emergency Room & Hospital Visits
Asthma TriggersAsthma Triggers
Attitudes About Living With Asthma
Information Sources for Asthma
Type of Doctor Seen for Asthma
Medication Usage
Use of a Peak Flow Meter
Use of Rescue Inhaler
Refill of Rescue Inhaler & Number of Units
Type of Inhaler Preferred
Lifestyle Changes to Help Control Asthma
Foods That Help Reduce Asthma Symptoms
Foods & Ingredients Avoid to Lessen Asthma Symptoms
Satisfaction With Aspects of Managing Asthma
Self Assessment of Ability to Control Asthma
Challenges in Controlling Asthma
Concern About Cost of Asthma Treatment & Prevention
Section 3: Asthma & Allergies
Incidence of Allergies Among Medicators
How Seasonal AllergiesSeasonal Allergies are Treated
Section 4: Rx Brand Awareness & Usage
Awareness of Rx Asthma Medication Brands
Advertising Awareness for Rx Asthma Medication Brands
Rx Asthma Medication Brands Used
Current Usage of Rx Asthma Medication Brands
Requests for Rx Medication
Section 5: Rx Medication Usage Patterns
Number & Frequency of Prescription Medications Taken
Forms of Rx Medication Used
Satisfaction With Rx Medication
Switching to a New Prescription
Brands Discontinued Versus Switched To
Satisfaction With Current Prescription Regimen
Section 6: Non-Rx Medication Usage Patterns
Details of Non-Rx Medication Usage
Use of Non-Rx Medication Brands for Asthma
Satisfaction With Effectiveness of Non-Rx Medication
Section 7: Impact of COVID-19
Rating of Disruption of COVID-19
Perception of How Long Until Country Will be Back to Normal
SEGMENTATION
For more information about this report visit https://www.researchandmarkets.com/r/irdkww
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.